Nicola Fabbri, MD
Pediatric and Adult Bone and Soft Tissue Sarcomas; Metastatic & Benign Bone Tumors; Pediatric and Adult Complex Limb & Joint Preservation & Reconstruction; Pelvic and Sacral Tumors; Periacetabular Tumors Resection and Reconstruction; Spino-Pelvic Reconstruction; Preoperative 3D Planning and Computer-Assisted Intra-Operative Navigation for Complex Surgery; Revision Surgery for Failed Lower Limb Reconstruction; Massive Bone Loss; Avascular Necrosis
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Fabbri accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, University of Bologna Medical School
Orthopedic Surgery - Istituto Otopedico Rizzoli
Adult Reconstruction - Mayo Clinic; Musculoskeletal Oncology - Mayo Clinic
Orthopaedic Surgery (Italy and Europe)
I am a surgeon with 20 years of experience in caring for children, teenagers, and adults with musculoskeletal cancers. This includes diagnosis and surgery for osteosarcoma, Ewing sarcoma, chondrosarcoma, soft tissue sarcomas, giant-cell tumor, chordoma, adamantinoma, osteofibrous dysplasia, angiosarcoma, and other vascular tumors of the extremities, pelvis, and sacrum. I also have expertise in treating metastatic bone cancer in the same parts of the body. My goal is to provide an individualized approach to each person I care for. I base my care on the diagnosis, location, and extent of a tumor, as well as a person’s age, activity level, and expectations.
I have expertise in a variety of surgical strategies and complex limb-salvage techniques. These include biologic, prosthetic, and hybrid reconstructions, as well as custom-designed implants and the use of 3-D technology. These techniques are aimed at helping people with cancer return to a level of functioning that is normal for them.
I also have a strong interest in nononcologic skeletal and joint reconstruction. I am especially focused on reconstructions associated with massive bone loss and deformities. In particular, I help children and young adults with avascular necrosis due to the treatment of blood cancers.
People with musculoskeletal cancers often require complex care and several different types of treatments. I am part of a multidisciplinary team with experts in other fields. These include pathology, medical oncology, radiation oncology, and other surgical specialties. We all share the ultimate goal of providing the best care to each individual patient.
This team approach has substantially improved the prognosis for people with sarcomas and musculoskeletal cancer in general. Effective tumor removal without amputation is now possible for most people. We use an individualized limb-preserving strategy and reconstructive technique. This puts the emphasis on providing patients with the most-functional and most-durable reconstruction.
My research focuses on understanding the biology and natural history of sarcomas. I investigate improving the management of musculoskeletal cancer and optimizing the function and durability of skeletal reconstructions. At MSK, we are working on designing more-effective cooperative strategies of treatment and advanced results of surgical management. This includes both limb-reconstructive surgery and, when necessary, amputations. My current areas of particular interest are 3-D printing technology, custom-made implants, and the use of new porous materials to restore bone and address massive bone loss and complex joint reconstruction.
I am a professor of surgery at Weill Cornell Medical College. I am a member of numerous national and international scientific societies related to musculoskeletal oncology and orthopedics, and I serve on several of their governing committees. I am on the advisory panel of the National Comprehensive Cancer Network for bone cancer guidelines.
I have trained and mentored several specialists and leaders in this field from all over the world.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Picci P, Manfrini M, Fabbri N, Gambarotti M, Vanel D (eds). Atlas of Musculoskeletal Tumors and Tumorlike Lesions: The Rizzoli Case Archive. New York: Springer; 2014.
Selected Publications & Book Chapters
Campanacci M, Capanna R, Fabbri N, Bettelli G. Curettage of giant cell tumor of bone. Reconstruction with subchondral grafts and cement. Chir Organi Mov 1990; 75:212-213.
Capanna R, Briccoli A, Biagini R, Casadei R, Fabbri N, Guernelli N, Campanacci M. Sacral resections: experience of the I.O.R. bone tumor center. Chir Organi Mov 1990; 75:114-116.
Bertoni F, Bacchini P, Fabbri N, Mercuri M, Picci P, Ruggieri P, Campanacci M. Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer 1993; 71:338-345.
Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, Baldini N, Ferrari S, Mercuri M, Ruggieri P, Caldora P, Benassi MS, Fabbri N, Monti C, Campanacci M. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing’s sarcoma of the extremities. J Clin Oncol 1993; 11:1763-1769.
Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: an updated report. J Clin Oncol 2000; 18:4016-4027.
Fabbri N, Mercuri M, Campanacci M. Resection of ischiopubic tumours (pelvic region 3). Editions Scientifiques et Médicales Elsevier SAS. Surgical Techniques in Orthopaedics and Traumatology, 55-470-D-10, 2001, 5 p.
Bacci G, Fabbri N, Balladelli A, Forni C, Palmerini E, Picci P. Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients. J Bone Joint Surg Br 2006; 88:1071-1075.
Bacci G, Balladelli A, Forni C, Longhi A, Serra M, Fabbri N, Alberghini M, Ferrari S, Benassi MS, Picci P. Ewing’s sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours. J Bone Joint Surg Br 2007; 89:1229-1233.
Bacci G, Ferrari S, Mercuri M, Longhi A, Fabbri N, Galletti S, Forni C, Balladelli A, Serra M, Picci P. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop 2007; 78:377-384.
Bacci G, Balladelli A, Forni C, Ferrari S, Longhi A, Bacchini P, Alberghini M, Fabbri N, Benassi M, Briccoli A, Picci P. Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer 2007; 109:780-786.
Bacci G, Longhi A, Forni C, Fabbri N, Briccoli A, Barbieri E, Mercuri M, Balladelli A, Ferrari S, Picci P. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. Int J Radiat Oncol Biol Phys 2007; 67:505-511.
Fabbri N, Rustemi E, Masetti C, Kreshak J, Gambarotti M, Vanel D, Toni A, Mercuri M. Severe osteolysis and soft tissue mass around total hip arthroplasty: description of four cases and review of the literature with respect to clinico-radiographic and pathologic differential diagnosis. Eur J Radiol 2011; 77:43-50.
Ferrari S, Palmerini E, Fabbri N, Staals E, Ferrari C, Alberghini M, Picci P. Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years. Tumori 2012;98: 702-708.
Fabbri N, O’Connor MI, Mercuri M, Sim FH: Iliofemoral Arthrodesis and Pseudoarthrosis. In: Master Techniques in Orthopaedic Surgery: Oncology and Complex Reconstruction. Lippincott Williams & Wilkins; 2012: 13-29.
Fabbri N, Turcotte R: Osteofibrous dysplasia. In: Encyclopédie. Médico-Chirurgicale: Techniques Chirurgicales, Orthopédie-Traumatologie, Paris, 2012.
Turcotte R, Fabbri N: Adamantinoma. In: Encyclopédie. Médico-Chirurgicale: Techniques Chirurgicales, Orthopédie-Traumatologie, Paris, 2012.
Gounder M, Yamada J, Fabbri N. Sarcomas of soft tissue and bone. In: The American Cancer Society Textbook of Clinical Oncology, 3rd ed. Atlanta, GA: American Cancer Society; 2013.
Fabbri N. CORR Insights®: survival, recurrence, and function after epiphyseal preservation and allograft reconstruction in osteosarcoma of the knee. Clin Orthop Relat Res 2015 May;473(5):1797-801.
Visit PubMed for a full listing of Dr. Fabbri’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Nicola Fabbri discloses the following relationships and financial interests:
Smith & Nephew
Provision of Services
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.